Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Lucila Nassif Kerbauy(Hospital Israelita Albert Einstein), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center)
Cited by 149
Related Papers
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
|Nature Medicine|2024|452
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
|Blood|2020|284
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
|Frontiers in Immunology|2015|267
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells
|Journal of Clinical Investigation|2021|245
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|236